Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by State Street Corp

State Street Corp raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 27.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,295 shares of the company’s stock after purchasing an additional 2,611 shares during the quarter. State Street Corp’s holdings in Structure Therapeutics were worth $540,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in GPCR. Point72 Asset Management L.P. raised its position in shares of Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after buying an additional 820,589 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Vestal Point Capital LP raised its holdings in shares of Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. First Light Asset Management LLC lifted its stake in shares of Structure Therapeutics by 296.1% in the 2nd quarter. First Light Asset Management LLC now owns 590,647 shares of the company’s stock valued at $23,195,000 after purchasing an additional 441,534 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after purchasing an additional 383,635 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $27.76 on Friday. The firm has a 50-day moving average of $33.28 and a two-hundred day moving average of $37.18. The stock has a market cap of $1.59 billion, a P/E ratio of -37.51 and a beta of -2.78. Structure Therapeutics Inc. has a 1-year low of $25.90 and a 1-year high of $62.74.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GPCR shares. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $86.50.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.